Reviews
Systematic reviews
Search a topic, title, author or review id. The Findings tab shows what the reviews found for the same words, grouped by question; the Studies tab shows the primary studies they include.
38 reviews, newest first
Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
Cochraneheadline outcomes only
6 findings
Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
Cochraneheadline outcomes only
9 findings
Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta‐analysis
Cochraneheadline outcomes only
43 findings
Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants
Cochraneheadline outcomes only
4 findings
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Cochraneheadline outcomes only
8 findings
Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta‐analysis
Cochraneheadline outcomes only
161 findings
Inhaled corticosteroids for the treatment of COVID‐19
Cochraneheadline outcomes only
7 findings
Inhaled corticosteroids for cystic fibrosis
Cochraneheadline outcomes only
7 findings
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
Cochraneheadline outcomes only
8 findings
Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth
Cochraneheadline outcomes only
5 findings
Inhaled corticosteroids for bronchiectasis
Cochraneheadline outcomes only
10 findings
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Cochraneheadline outcomes only
10 findings
Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
Cochraneheadline outcomes only
7 findings
Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates
Cochraneheadline outcomes only
3 findings
Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants
Cochraneheadline outcomes only
11 findings
Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates
Cochraneheadline outcomes only
11 findings
Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
Cochraneheadline outcomes only
18 findings
Stepping down the dose of inhaled corticosteroids for adults with asthma
Cochraneheadline outcomes only
14 findings
Interventions to improve adherence to inhaled steroids for asthma
Cochraneheadline outcomes only
24 findings
Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
Cochraneheadline outcomes only
7 findings
Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children
Cochraneheadline outcomes only
14 findings
Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Cochraneheadline outcomes only
7 findings
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
Cochraneheadline outcomes only
7 findings
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
Cochraneheadline outcomes only
7 findings
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta₂‐agonists (LABA) for adults with asthma
Cochraneheadline outcomes only
7 findings